These results reveal a presumptive mechanism for the pathogenesis of APOA4 amyloidosis and suggest that TFEB activators, including trehalose (35, 89), may be a therapeutic strategy for CKD-related metabolic disorders and age-related APOA4 amyloidosis. Here, TFEB is linked to Other metabolic disease.